The Relative Strength (RS) Rating for Stryker headed into a higher percentile Tuesday, as it got a lift from 70 to 75.
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Stryker can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Stryker broke out earlier, but has fallen back below the prior 398.20 entry from a cup without handle. If a stock you're tracking clears a buy point then declines 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new chart pattern and entry price. Also keep in mind that the latest consolidation is a later-stage base, and those involve more risk.
The company posted 16% EPS growth in the latest quarterly report, while sales growth came in at 11%.
Stryker earns the No. 6 rank among its peers in the Medical-Products industry group. Boston Scientific, LeMaitre Vascular and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
